

1 Attitudes toward COVID-19 illness and COVID-19 vaccination among pregnant women: a cross-
2 sectional multicenter study during August-December 2020

3
4 Ashley N. Battarbee¹, Melissa S. Stockwell^{2,3,4}, Michael Varner⁵, Gabriella Newes-Adeyi⁶,
5 Michael Daugherty⁷, Cynthia Gyamfi-Bannerman^{4,8}, Alan Tita¹, Kelly Vorwaller⁵, Celibell
6 Vargas², Akila Subramaniam¹, Lawrence Reichle⁶, Romeo Galang⁷, Emily Powers⁵, Miriam
7 Lucca-Susana^{4,8}, Mickey Parks¹, Tiffany J. Chen⁷, Hilda Razzaghi⁷, Fatimah S. Dawood⁷

8

9 **Affiliations:**

10 (1) Center for Women's Reproductive Health and Department of Obstetrics and
11 Gynecology, Division of Maternal-Fetal Medicine, University of Alabama at Birmingham

12 (2) Division of Child and Adolescent Health, Department of Pediatrics, Columbia University
13 Irving Medical Center, New York, NY

14 (3) Department of Population and Family Health, Mailman School of Public Health,
15 Columbia University Irving Medical Center, New York, NY

16 (4) New York-Presbyterian Hospital, New York, NY

17 (5) Department of Obstetrics and Gynecology, University of Utah Health Sciences Center,
18 Salt Lake City, Utah

19 (6) Abt Associates, Bethesda, MD

20 (7) Centers for Disease Control and Prevention, Atlanta, GA

21 (8) Department of OBGYN, Division of Maternal-Fetal Medicine, Columbia University Irving
22 Medical Center

23

24 **Disclosures:** Author CGB has an unrestricted grant from SMFM/AMAG to study prematurity.

25

26 **Funding:** This study was funded by the US Centers for Disease Control and Prevention through
27 Contract # 75D30120C08150 with Abt Associates.

28
29 **Disclaimer:** The findings and conclusions in this report are those of the authors and do not
30 necessarily represent the official position of the Centers for Disease Control and
31 Prevention/Agency for Toxic Substances and Disease Registry, US Department of Health and
32 Human Services.

33
34 **Corresponding Author:**

35 Ashley N. Battarbee
36 Center for Women's Reproductive Health and Department of Obstetrics and Gynecology,
37 Division of Maternal-Fetal Medicine, University of Alabama at Birmingham
38 1700 6th Ave South, Rm 10270
39 Birmingham, AL 35233
40 Phone: 205-934-5612
41 E-mail: anbattarbee@uabmc.edu

42

43 ABSTRACT

44 **Objective:** Evaluate pregnant women’s attitudes toward COVID-19 illness and vaccination and
45 identify factors associated with vaccine acceptability.

46 **Study Design:** Cross-sectional survey among pregnant women enrolled in a prospective
47 COVID-19 cohort study in Salt Lake City, UT, Birmingham, AL, and New York, NY, August 9–
48 December 10, 2020. Women were eligible if they were 18-50 years old and <28 weeks of
49 gestation. Upon enrollment, women completed surveys regarding concerns about COVID-19
50 illness and likelihood of getting COVID-19 vaccine if one were available during pregnancy.
51 Vaccine acceptability was defined as a response of “very likely” or “somewhat likely” on a 4-
52 point Likert scale. Factors associated with vaccine acceptability were assessed with
53 multivariable logistic regression.

54 **Results:** Of 939 pregnant women eligible for the main cohort study, 915 (97%) consented to
55 participate. Among these 915 women, 39% self-identified as White, 23% Black, 33% Hispanic,
56 and 4% Other. Sixty-two percent received an influenza vaccine last season. Seventy-two
57 percent worried about getting sick with COVID-19. If they were to get sick, 92% worried about
58 harm to their pregnancy and 80% about harm to themselves. Only 41% reported they would get
59 a vaccine. Of women who were unlikely to get vaccinated, the most frequently cited concern
60 was vaccine safety for their pregnancy (82%). Non-Hispanic Black and Hispanic women had
61 lower odds of accepting a vaccine compared with non-Hispanic White women (adjusted odds
62 ratios (aOR) 0.4, 95%CI 0.2–0.6 for both). Receipt of influenza vaccine during the previous
63 season was associated with higher odds of vaccine acceptability (aOR 2.1, 95%CI 1.5-3.0).

64 **Conclusion:** Although most pregnant women worried about COVID-19 illness, <50% were
65 willing to get vaccinated during pregnancy. Racial and ethnic disparities in plans to accept
66 COVID-19 vaccine highlight the need to prioritize strategies to address perceived barriers
67 among groups at high risk for COVID-19.

68

69 INTRODUCTION

70 As of March 1, 2021, there have been over 114 million cases of COVID-19 with
71 more than 2.5 million deaths worldwide(1). Of the 1.1 million cases in the United States,
72 there have been more than 73,000 laboratory-confirmed cases of COVID-19 among
73 pregnant women(2). Based on accumulating data, pregnant women appear to be at
74 increased risk for severe COVID-19 disease(3, 4). In a recent report that included
75 400,000 women of reproductive age, pregnant women with COVID-19 were found to be
76 more likely than non-pregnant women to be admitted to the intensive care unit, receive
77 extracorporeal membrane oxygenation, and die(5). Comparisons of rates of SARS-CoV-
78 2 infection and risks for COVID-19 disease among pregnant versus non-pregnant
79 women in the United States also suggest that Hispanic women may be at increased risk
80 of infection and Hispanic and non-Hispanic Black women may be at increased risk of
81 severe disease(5, 6). At this time, the risk of transplacental transmission of COVID-19 to
82 the developing fetus appears to be low,(7, 8) and most studies have shown no
83 increased risk of spontaneous abortions or stillbirth(9, 10). However, pregnant women
84 with COVID-19 illness may be at increased risk for preterm birth(11).

85 Although social distancing, hand hygiene, and mask wearing are key non-
86 pharmaceutical interventions to slow the spread of COVID-19, widespread safe and
87 effective vaccination is ultimately necessary to control this global pandemic(12). Many
88 COVID-19 vaccine trials are currently being conducted worldwide with many vaccines in
89 Phase III testing and now a few COVID-19 vaccines approved for emergency use (14,
90 15). Pregnant women have not been included in the Phase III trials. However, both the
91 American College of Obstetricians and Gynecologists (ACOG) and the Society for

92 Maternal Fetal Medicine (SMFM) recommend that pregnant women be included in
93 vaccine trials and offered COVID-19 vaccines (16, 17). In addition, the Centers for
94 Disease Control and Prevention recommends that pregnant women be provided the
95 opportunity to choose whether to receive COVID-19 vaccine under the current
96 Emergency Use Authorization(18, 19). However, the willingness of pregnant women to
97 be vaccinated is unknown.

98 We evaluated pregnant women’s attitudes toward COVID-19 illness and
99 vaccination during pregnancy and assessed factors associated with vaccine
100 acceptability. Based on findings from studies of influenza vaccine acceptance among
101 adults,(20) we hypothesized that women from racial and ethnic minority groups would
102 be less willing to be vaccinated.

103

104 **METHODS**

105 We performed a cross-sectional study of pregnant women enrolled August 9–
106 December 10, 2020, in the Epidemiology of Severe Acute Respiratory Syndrome in
107 Pregnancy and Infancy (ESPI) Community Cohort, an ongoing prospective longitudinal
108 cohort study conducted at three centers in the United States (Birmingham, AL; Salt
109 Lake City, UT; and New York, NY). The ESPI Community Cohort study is designed to
110 estimate the incidence of SARS-CoV-2 infection, identify risk factors for infection, and
111 characterize the clinical spectrum of infection among pregnant women receiving
112 prenatal care at the three study sites. Centralized Institutional Review Board approval
113 was obtained (IRB-AAAT1906), and informed consent was obtained from all
114 participants.

115 Women were eligible for participation in the main cohort if they were 18–50 years
116 old and were at less than 28 weeks of gestation to allow for an average of at least 12
117 weeks of surveillance time in the cohort prior to end of pregnancy. Women without a
118 functioning telephone and those who were not willing to respond to weekly COVID-19
119 surveillance questionnaires or to self-collect nasal swabs weekly were not eligible for
120 participation, as these were key components of the ESPI Community Cohort study.
121 Additionally, women who were unable to speak and read either English or Spanish, and
122 those currently enrolled in a COVID-19 or influenza vaccine trial, were not eligible.
123 Women were not excluded based on prior suspected or confirmed COVID-19 infection.
124 Study staff attempted to approach all women who met age and gestational age criteria
125 for enrollment among those receiving prenatal care at the three participating centers
126 during the study period. Participants were recruited over the phone and in person at
127 outpatient prenatal care offices.

128 Women who consented to participate in the ESPI Community Cohort were asked
129 to complete a standardized survey at the time of study enrollment. The survey included
130 questions about maternal demographics and socioeconomic characteristics, past
131 medical and obstetric history, and attitudes towards SARS-CoV-2 infection/COVID-19
132 illness and vaccination in pregnancy. Women were considered fully enrolled in the main
133 ESPI Community Cohort study if they consented to participation and completed eight
134 core questions on the enrollment survey about enrollment date, estimated delivery date,
135 number of gestations, diagnosis of gestational hypertension or gestational diabetes
136 during the current pregnancy, presence of underlying medical conditions, and number of
137 prior pregnancies.

138 Using a 4-point Likert scale, pregnant women were asked “How worried are you
139 about getting sick with COVID-19?” as well as “If you were to get sick with COVID-19,
140 how worried are you that COVID-19 would harm you?” and “...how worried
141 are you that COVID-19 would harm your pregnancy?” Women were deemed concerned
142 if they answered “very worried” or “somewhat worried.” Women were asked about their
143 most trusted source for receiving information about COVID-19, and women were also
144 asked “If a COVID-19 vaccine were to become available for pregnant women, how likely
145 would you be to get the vaccine for yourself during your pregnancy?” Vaccine
146 acceptability was defined as women who answered “very likely” or “somewhat likely.”
147 Women were considered not willing to get a vaccine if they answered “not too likely” or
148 “not at all likely.” Lastly, women were asked to answer multiple choice questions about
149 the reasons why they would (or would not) get a vaccine; in addition to standard
150 response choices, questions included an option to indicate other reasons with free text
151 entry. Answer choices for reasons for getting the vaccine included: “to protect myself
152 from getting sick with COVID-19”, “to protect my pregnancy,” “to protect others in my
153 family,” and “to protect others in the community from getting sick with COVID-19.”
154 Answer choices for reasons for not getting the vaccine included: “concerns or question
155 about vaccine safety for myself,” “concerns or questions about vaccine safety for my
156 pregnancy,” “concerns or questions about whether the vaccine would work to protect
157 me from COVID-19,” and “I don’t think I need the vaccine.”

158 A complete case analysis was performed including women who enrolled in the
159 cohort study from August 9 to December 10, 2020. Baseline maternal demographic and
160 obstetric characteristics in the population were described in aggregate and by vaccine

161 acceptability. Descriptive statistics were used to summarize pregnant women's
162 responses to questions about COVID-19 illness and vaccination during pregnancy.
163 Logistic regression was used to estimate the association between baseline
164 characteristics and vaccine acceptability. Key characteristics assessed included study
165 site, maternal age, self-reported race and ethnicity, education, employment status,
166 employment in a healthcare occupation, household income, maternal medical
167 comorbidities, and prior receipt of influenza vaccination during the 2019–20 influenza
168 season. Race and ethnicity were characterized as Black if women identified as Non-
169 Hispanic Black or African American, White if women identified as Non-Hispanic White,
170 and Hispanic if women identified as Hispanic or Latino regardless of race. All
171 characteristics that were significantly associated with vaccine acceptability in
172 unadjusted analyses at $p < 0.20$ were included in the multivariable logistic regression
173 model, except for study site and employment status, which were highly correlated with
174 other covariates. Backward step-wise selection using a p-value cut-off of 0.2 and
175 evaluating for a $>10\%$ change in adjusted odds ratios was used to achieve a final,
176 parsimonious model from which adjusted odds ratios and 95% confidence intervals (CI)
177 were estimated. To assess for differences in predictors of vaccine acceptability before
178 and after the first release of phase III COVID-19 vaccine trial results in the United States
179 in early November 2020, multivariable models were run among all women and stratified
180 by women who completed enrollment surveys during August 9-November 14 and
181 November 15-December 20, 2020 using the same explanatory variables selected for
182 the final primary model. Adjusted odds ratios and 95% confidence intervals (CI) were
183 estimated.

184 The associations between: (1) women’s level of concern about getting sick with
185 COVID-19 and (2) women’s level of concern about harm to themselves or their
186 pregnancy from COVID-19 in the setting of SARS-CoV-2 infection and vaccine
187 acceptance were also assessed using bivariate analysis.

188 SAS Version 9.4 was used for statistical analysis, and statistical significance was
189 set at $p=0.05$.

190

191 **RESULTS**

192 During the study period, 1186 women were screened for eligibility for the main
193 cohort study, of whom 939 (79%) were eligible. Among these 939 women, 915 (97%)
194 consented to participate in the main cohort study and were fully enrolled.

195 Among the 915 women included in this analysis, 39% self-identified as White,
196 23% as Black, and 33% as Hispanic. Overall, 64% of women had more than a high
197 school education, 60% were employed, and 20% lived in households with income below
198 the local poverty line. Twenty-eight percent of women had one or more underlying
199 medical conditions. Last season 62% of women reported receiving the influenza vaccine
200 (Table 1).

201 Seventy-two percent (95% CI: 69%-75%) of women stated they were worried
202 about getting sick with COVID-19. If they were to get sick with COVID-19, 92% (95% CI:
203 91%-94%) of women were worried that COVID-19 would harm their pregnancies, and
204 80% (95% CI: 77%-82%) were worried that COVID-19 would harm them (Figure 1).
205 When asked what source of COVID-19 information women trusted the most, the most
206 common answer was their obstetrician/gynecologist (42%, 95% CI: 38%-45%), followed

207 by their family doctor or primary care provider (28%, 95% CI: 25%-30%), CDC (13%,
208 95% CI: 11%-15%), and other medical professionals (4%, 95% CI: 3%-5%).

209 Overall, 41% (374/915, 95% CI: 38%-44%) of women reported they would get a
210 COVID-19 vaccine if one became available during their pregnancy. When stratified by
211 enrollment month, the proportion of women willing to get a COVID-19 vaccine was
212 similar (data not shown). Among women who were willing to get a vaccine during
213 pregnancy, the most commonly cited reason for vaccine acceptability was to protect
214 their pregnancy (95%, 95% CI: 93%-98%). Other reasons included protecting
215 themselves (85%, 95% CI: 81%-89%), protecting family members (79%, 95% CI: 75%-
216 83%), and protecting the community (68%, 95% CI: 63%-73%). In contrast, women who
217 were not willing to get a vaccine during pregnancy most frequently cited concerns about
218 vaccine safety for their pregnancy (82%, 95% CI: 78%-85%). Other reasons included
219 concerns about vaccine safety for themselves (68%, 95% CI: 63%-72%), vaccine
220 effectiveness (52%, 95% CI: 47%-56%), and the belief that they did not need the
221 vaccine (22%, 95% CI: 18%-26%).

222 Pregnant women's willingness to accept a COVID-19 vaccine varied by maternal
223 race and ethnicity as well as other baseline characteristics. Women who were non-
224 Hispanic White were more likely to be willing to accept the vaccine than women who
225 were non-Hispanic Black or Hispanic (Figure 2). For example, 63% (95% CI: 58%-69%)
226 of women who were non-Hispanic White stated that they were either very likely or
227 somewhat likely to accept the vaccine whereas only 31% (95% CI: 25%-38%) of non-
228 Hispanic Black and 35% (95% CI: 29%-41%) of Hispanic women were very likely or
229 somewhat likely to accept the vaccine. Stated otherwise, 69% (95% CI: 62%-75%) of

230 non-Hispanic Black and 65% (95% CI: 59%-71%) of Hispanic women were not likely to
231 receive the vaccine compared to only 37% (95% CI: 31%-42%) of non-Hispanic White
232 women. In addition to maternal race and ethnicity, Utah study site, having a graduate
233 school degree, and getting an influenza vaccine during the 2019-2020 influenza season
234 were also associated with COVID-19 vaccine acceptability (Table 2). However, in
235 adjusted models that included race and ethnicity, educational level, and getting an
236 influenza vaccine during the 2019-2020 influenza season, only race and ethnicity and
237 prior influenza vaccine acceptance were significantly associated with willingness to get
238 a COVID-19 vaccine (Table 2). Women who self-identified as non-Hispanic Black and
239 women who identified as Hispanic had lower odds of accepting a COVID-19 vaccine
240 compared to non-Hispanic White women (adjusted odds ratio [aOR] 0.4, 95% CI 0.2–
241 0.6 for each comparison). In contrast, women who reported getting the 2019-2020
242 influenza vaccine had higher odds of accepting a COVID-19 vaccine compare to those
243 who did not (aOR 2.1, 95% CI 1.5-3.0). Model findings were consistent among women
244 who completed the enrollment survey during August 9-November 14, 2020 versus
245 November 14-December 10, 2020.

246 Women who were worried about getting sick with COVID-19 were more likely to
247 say they would get a COVID-19 vaccine during pregnancy than women who were not
248 worried about getting sick (49% vs. 40%, $p=0.01$). Women's worry about COVID-19
249 illness harming themselves and their pregnancies in the setting of COVID-19 illness was
250 not significantly associated with vaccine acceptability ($p=0.24$ and $p=0.60$, respectively).

251

252 **DISCUSSION**

253 In this cross-sectional study of more than 900 pregnant women from three
254 diverse centers across the U.S., three-fourths were concerned about getting sick with
255 COVID-19 and worried that COVID-19 could harm themselves and their pregnancies.
256 However, less than half of pregnant women in this study said they would be likely to get
257 a COVID-19 vaccine if one were available during their pregnancy, although this was
258 consistent with data from a national survey of the general adult population in the US
259 from the same period(21). Pregnant Black and Hispanic women were less likely to be
260 willing to get a COVID-19 vaccine than White women. Women who received an
261 influenza vaccine during the previous season were more likely to be accepting of a
262 COVID-19 vaccine. Common perceived barriers to vaccination among women who were
263 unwilling to get a COVID-19 vaccine included concerns about vaccine safety for their
264 pregnancies and themselves, and concerns about vaccine effectiveness. Three in four
265 pregnant women identified healthcare professionals as their most trusted source of
266 information about COVID-19, with 41% specifying their obstetrician/gynecologist.

267 Previous studies of influenza vaccination in pregnancy have identified similar
268 perceived barriers to vaccination to those found in our study, including concerns about
269 vaccine safety and effectiveness and similar perceived benefits including providing
270 protection to the pregnancy(22). Healthcare provider recommendation is one of the
271 strongest and most consistent predictors of influenza vaccination in the United States
272 and globally(22, 23). In our study, we also found that the majority of women identified
273 healthcare providers as their most trusted source of information about COVID-19 and
274 prior receipt of influenza vaccine was associated with higher odds of COVID-19 vaccine
275 acceptability. Our findings, coupled with findings related to acceptance of other currently

276 recommended vaccines during pregnancy, indicate that obstetricians and other
277 healthcare providers will play a critical role in counseling pregnant women about the
278 risks of COVID-19 illness and providing information about the safety and effectiveness
279 of COVID-19 vaccines. Currently, both ACOG and SMFM advocate that pregnant
280 women have the option to receive COVID-19 vaccines, and that shared decision-
281 making be utilized by each pregnant woman and her provider regarding vaccination(16,
282 17). CDC also provides guidance and resources for healthcare professionals to discuss
283 vaccination with patients before and as COVID-19 vaccines become more widely
284 available in the United States ([https://www.cdc.gov/vaccines/covid-19/hcp/engaging-](https://www.cdc.gov/vaccines/covid-19/hcp/engaging-patients.html)
285 [patients.html](https://www.cdc.gov/vaccines/covid-19/hcp/engaging-patients.html)).

286 In this study, Black race and Hispanic ethnicity were associated with lower odds
287 of COVID-19 vaccine acceptability. These findings must be considered in the context of
288 the well-documented history of unethical medical experimentation among racial and
289 ethnic minority populations in the United States that has engendered mistrust of medical
290 interventions among some communities as well as racial and ethnic disparities in key
291 social determinants of health that may influence vaccine acceptability(24). For example,
292 two recent studies in the United States found that Black women were less likely to
293 report receiving a healthcare provider offer or referral for influenza or Tdap vaccination
294 and had lower rates of receipt of both vaccines during pregnancy(25, 26). In addition,
295 several studies have now documented that SARS-CoV-2 infection rates in the United
296 States are higher among Black and Hispanic communities and identified disparities in
297 COVID-19 severity among pregnant women from these groups(5, 27). For example, in a
298 recent *Morbidity and Mortality Weekly Report*, non-Hispanic Black or African American

299 women represented 27% of COVID-19 deaths in pregnancy, but comprised only 15% of
300 infected pregnant women(5). In the same analysis, pregnant Hispanic women
301 experienced SARS-CoV-2 infection at a disproportionately higher rate compared to non-
302 pregnant Hispanic women. Our findings that women who face a greater risk of harm
303 from COVID-19 infection are less willing to accept COVID-19 vaccination highlight the
304 need for outreach and communication strategies to address perceived barriers to
305 vaccination among groups that may be less likely to get a COVID-19 vaccine.

306 Our study has several strengths. Our population was comprised of a diverse
307 group of pregnant women from three different centers across the United States. Efforts
308 were made to approach all women receiving prenatal care at study clinics for study
309 participation in the main cohort to optimize representation of the study source
310 population. The survey collected detailed information about common perceived
311 motivators and barriers to vaccination, tailored specifically for the contexts of pregnancy
312 and the COVID-19 pandemic.

313 Several limitations should be considered when interpreting study findings. While
314 the study was designed to maximize diversity and generalizability, only women who had
315 access to prenatal care and who consented to participate in the prospective cohort were
316 included. Thus, our results may not be generalizable to all pregnant women. We also
317 did not enroll a non-pregnant group, and thus we cannot comment about how these
318 findings may differ from a non-pregnant population in the same communities. Given that
319 this study was conducted before a COVID-19 vaccine was available in the United
320 States, we could not assess factors associated with actual vaccine receipt and our
321 findings are based on hypothetical acceptability of a COVID-19 vaccine. In addition, as

322 with all surveys, our findings may be subject to social desirability bias in which
323 participants are more likely to respond in a manner that they perceive to be socially
324 acceptable. Vaccine acceptance as well as perceived motivators and barriers to
325 acceptance may evolve among pregnant women as additional data about COVID-19
326 vaccine safety and efficacy become available. Additional studies will be needed to
327 monitor trends in vaccine acceptance among pregnant women over time.

328 Widespread vaccination is the most promising strategy to end the current global
329 pandemic, while hand-washing, social distancing, mask wearing and other key non-
330 pharmaceutical interventions will remain important mainstays of COVID-19 prevention.
331 The results of this study provide insight into potential racial and ethnic disparities in
332 COVID-19 vaccine acceptability among pregnant women. When a vaccine is available
333 to pregnant women in the United States, obstetricians and other health care providers
334 will play a critical role in counseling pregnant women about COVID-19 illness and
335 offering COVID-19 vaccine to pregnant women. Similar to influenza vaccination, a clear
336 recommendation by obstetric care professionals to pregnant women to take the vaccine
337 will likely increase COVID-19 vaccine uptake. This may be especially important for
338 pregnant women in racial and ethnic groups who may be at greater risk for infection and
339 severe disease and who also appear to be less likely to accept a vaccine at this time
340 based on the findings of our study. In order to overcome these disparities, outreach
341 programs with community collaboration may be important to customize patient
342 education materials that improve communication and shared decision-making in order
343 to achieve health equity in vaccination during pregnancy.

344

345 REFERENCES

- 346 1. Johns Hopkins University & Medicine. COVID-19 Dashboard by the Systems Science and
347 Engineering (CSSE). 2020 [cited 2020 12/9/2020]; Available from:
348 <https://coronavirus.jhu.edu/map.html>
- 349 2. Prevention CfDca. Data on COVID-19 during Pregnancy: Severity of Maternal Illness. 2020
350 [cited 2020 December 18]; Available from: [https://covid.cdc.gov/covid-data-tracker/#pregnant-](https://covid.cdc.gov/covid-data-tracker/#pregnant-population)
351 [population](https://covid.cdc.gov/covid-data-tracker/#pregnant-population)
- 352 3. Delahoy MJ, Whitaker M, O'Halloran A, Chai SJ, Kirley PD, Alden N, et al. Characteristics
353 and Maternal and Birth Outcomes of Hospitalized Pregnant Women with Laboratory-Confirmed
354 COVID-19 - COVID-NET, 13 States, March 1-August 22, 2020. *MMWR Morb Mortal Wkly Rep*
355 2020 Sep 25;69(38):1347-54.
- 356 4. Centers for Disease Control and Prevention. People with Certain Medical Conditions. 2020
357 [cited 2020 12/3/2020]; Available from: [https://www.cdc.gov/coronavirus/2019-ncov/need-extra-](https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html)
358 [precautions/people-with-medical-conditions.html](https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html)
- 359 5. Zambrano LD, Ellington S, Strid P, Galang RR, Oduyebo T, Tong VT, et al. Update:
360 Characteristics of Symptomatic Women of Reproductive Age with Laboratory-Confirmed SARS-
361 CoV-2 Infection by Pregnancy Status - United States, January 22-October 3, 2020. *MMWR*
362 *Morb Mortal Wkly Rep* 2020 Nov 6;69(44):1641-7.
- 363 6. Ellington S, Strid P, Tong VT, Woodworth K, Galang RR, Zambrano LD, et al. Characteristics
364 of Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by
365 Pregnancy Status - United States, January 22-June 7, 2020. *MMWR Morb Mortal Wkly Rep*
366 2020 Jun 26;69(25):769-75.
- 367 7. Dumitriu D, Emeruwa UN, Hanft E, Liao GV, Ludwig E, Walzer L, et al. Outcomes of
368 Neonates Born to Mothers With Severe Acute Respiratory Syndrome Coronavirus 2 Infection at
369 a Large Medical Center in New York City. *JAMA Pediatr* 2020 Oct 12.
- 370 8. Salvatore CM, Han JY, Acker KP, Tiwari P, Jin J, Brandler M, et al. Neonatal management
371 and outcomes during the COVID-19 pandemic: an observation cohort study. *Lancet Child*
372 *Adolesc Health* 2020 Oct;4(10):721-7.
- 373 9. Cosma S, Carosso AR, Cusato J, Borella F, Carosso M, Bovetti M, et al. Coronavirus disease
374 2019 and first-trimester spontaneous abortion: a case-control study of 225 pregnant patients.
375 *Am J Obstet Gynecol* 2020 Oct 8.
- 376 10. Panagiotakopoulos L, Myers TR, Gee J, Lipkind HS, Kharbanda EO, Ryan DS, et al. SARS-
377 CoV-2 Infection Among Hospitalized Pregnant Women: Reasons for Admission and Pregnancy
378 Characteristics - Eight U.S. Health Care Centers, March 1-May 30, 2020. *MMWR Morb Mortal*
379 *Wkly Rep* 2020 Sep 23;69(38):1355-9.
- 380 11. Woodworth KR, Olsen EO, Neelam V, Lewis EL, Galang RR, Oduyebo T, et al. Birth and
381 Infant Outcomes Following Laboratory-Confirmed SARS-CoV-2 Infection in Pregnancy - SET-
382 NET, 16 Jurisdictions, March 29-October 14, 2020. *MMWR Morb Mortal Wkly Rep* 2020 Nov
383 6;69(44):1635-40.
- 384 12. Lerner AM, Folkers GK, Fauci AS. Preventing the Spread of SARS-CoV-2 With Masks and
385 Other "Low-tech" Interventions. *JAMA* 2020 Nov 17;324(19):1935-6.
- 386 13. Zimmer C, Corum J, Wee S-L. Coronavirus Vaccine Tracker. 2020 [cited 2020
387 12/11/2020]; Available from: [https://www.nytimes.com/interactive/2020/science/coronavirus-](https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html?auth=link-dismiss-google1tap)
388 [vaccine-tracker.html?auth=link-dismiss-google1tap](https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html?auth=link-dismiss-google1tap)
- 389 14. U.S. Food and Drug Administration. Pfizer-BioNTech COVID-19 Vaccine Emergency Use
390 Authorization Letter. 2020 [cited 2020 12/14/2020]; Available from:
391 <https://www.fda.gov/media/144412/download>
- 392 15. Administration USFaD. Moderna COVID-19 Vaccine EUA Letter of Authorization. [cited
393 2020 December 21]; Available from: <https://www.fda.gov/media/144636/download>

- 394 16. Zahn CM. ACOG Statement on COVID-19 and Pregnancy. 2020 [cited 2020 11/30/2020];
395 Available from: [https://www.acog.org/news/news-releases/2020/06/acog-statement-on-covid-19-](https://www.acog.org/news/news-releases/2020/06/acog-statement-on-covid-19-and-pregnancy)
396 [and-pregnancy](https://www.acog.org/news/news-releases/2020/06/acog-statement-on-covid-19-and-pregnancy)
397 17. Society for Maternal-Fetal Medicine. Society for Maternal-Fetal Medicine (SMFM)
398 Statement: SARS-CoV-2 Vaccination in Pregnancy. 2020 [cited 2020 12/1/2020]; Available
399 from: [https://s3.amazonaws.com/cdn.smfm.org/media/2591/SMFM_Vaccine_Statement_12-1-](https://s3.amazonaws.com/cdn.smfm.org/media/2591/SMFM_Vaccine_Statement_12-1-20_(final).pdf)
400 [20_\(final\).pdf](https://s3.amazonaws.com/cdn.smfm.org/media/2591/SMFM_Vaccine_Statement_12-1-20_(final).pdf)
401 18. Centers for Disease Control and Prevention. Pregnancy and Breastfeeding Considerations.
402 2020 [cited 2020 12/14/2020]; Available from: [https://www.cdc.gov/coronavirus/2019-](https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/pregnancy.html)
403 [ncov/vaccines/recommendations/pregnancy.html](https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/pregnancy.html)
404 19. Centers for Disease Control and Prevention. Interim Clinical Considerations for Use of
405 Pfizer-BioNTech COVID-19 Vaccine. 2020 [cited 2020 12/14/2020]; Available from:
406 <https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/clinical-considerations.html>
407 20. Egede LE, Zheng D. Racial/ethnic differences in influenza vaccination coverage in high-risk
408 adults. *Am J Public Health* 2003 Dec;93(12):2074-8.
409 21. Nguyen K, Srivastav A, Razzaghi H, Williams W, Lindley M, Jorgensen C, et al. COVID-19
410 Vaccination Intent, Perceptions, and Reasons for Not Vaccinating Among Groups Prioritized for
411 Early Vaccination — United States, September and December 2020. *MMWR Morb Mortal Wkly*
412 *Rep* 2021;70(6):217–22.
413 22. Yuen CY, Tarrant M. Determinants of uptake of influenza vaccination among pregnant
414 women - a systematic review. *Vaccine* 2014 Aug 6;32(36):4602-13.
415 23. Myers KL. Predictors of maternal vaccination in the United States: An integrative review of
416 the literature. *Vaccine* 2016 Jul 25;34(34):3942-9.
417 24. Egede LE, Walker RJ. Structural Racism, Social Risk Factors, and Covid-19 - A Dangerous
418 Convergence for Black Americans. *N Engl J Med* 2020 Sep 17;383(12):e77.
419 25. Lindley MC, Kahn KE, Bardenheier BH, D'Angelo DV, Dawood FS, Fink RV, et al. Vital
420 Signs: Burden and Prevention of Influenza and Pertussis Among Pregnant Women and Infants -
421 United States. *MMWR Morb Mortal Wkly Rep* 2019 Oct 11;68(40):885-92.
422 26. Razzaghi H, Kahn KE, Black CL, Lindley MC, Jatlaoui TC, Fiebelkorn AP, et al. Influenza
423 and Tdap Vaccination Coverage Among Pregnant Women - United States, April 2020. *MMWR*
424 *Morb Mortal Wkly Rep* 2020 Oct 2;69(39):1391-7.
425 27. Moore JT, Ricaldi JN, Rose CE, Fuld J, Parise M, Kang GJ, et al. Disparities in Incidence of
426 COVID-19 Among Underrepresented Racial/Ethnic Groups in Counties Identified as Hotspots
427 During June 5-18, 2020 - 22 States, February-June 2020. *MMWR Morb Mortal Wkly Rep* 2020
428 Aug 21;69(33):1122-6.
429

430

431 **TABLES**

432

Table 1. Baseline demographic and other characteristics (n=915)				
	Total N=915 n (col %)	Willing to get vaccine* n=374 n (row %)	Not willing to get vaccine* n=429 n (row %)	p-value
Site				
Birmingham, AL	267 (29)	98/245 (40)	147/245 (60)	<0.01
Salt Lake City, UT	340 (37)	196/311 (63)	115/311 (37)	
New York City, NY	308 (34)	80/247 (32)	167/247 (68)	
Age, years				
18-34	741 (81)	295/647 (46)	352/647 (54)	0.22
35-50	172 (19)	79/155 (51)	76/155 (49)	
Race/ethnicity				
White, non-Hispanic	346 (39)	202/319 (63)	117/319 (37)	<0.01
Black, non-Hispanic	201 (23)	58/186 (31)	128/186 (69)	
Hispanic	293 (33)	83/238 (35)	155/238 (65)	
Other, non-Hispanic	38 (4)	16/30 (53)	14/30 (47)	
Education				
Less than high school diploma	57 (6)	23/52 (44)	29/52 (56)	<0.01
High school diploma	265 (29)	89/225 (40)	136/225 (60)	
Some college/technical school	230 (25)	63/191 (33)	128/191 (67)	
College degree	214 (23)	106/193 (55)	87/193 (45)	
Graduate degree	147 (16)	93/141 (66)	48/141 (34)	
Household below poverty level*	177 (20)	73/161 (45)	88/161 (55)	0.71
Marital status				
Married	473 (52)	235/425 (55)	190/425 (45)	<0.01
Never married	267 (30)	83/224 (37)	141/224 (63)	
Committed partnership	127 (14)	39/112 (35)	73/112 (65)	

Other	37 (4)	15/33 (45)	18/33 (55)	
Employed	549 (60)	239/493 (48)	254/493 (52)	0.23
Occupation [†]				
Healthcare professional	228 (42)	108/203 (53)	95/203 (47)	0.10
Other	316 (58)	130/285 (46)	155/285 (54)	
≥1 underlying medical condition [‡]	253 (28)	107/232 (46)	125/232 (54)	0.87
Previously had suspected/confirmed COVID-19 before enrollment	44 (5)	20/37 (54)	17/37 (46)	0.64
Received Influenza Vaccine Last Year	564 (62)	273/497 (55)	224/497 (45)	<0.01
<p>*Based on number of household members: https://aspe.hhs.gov/poverty-guidelines. Column % do not include missing.</p> <p>If data are missing for a variable, n included are indicated in parentheses after variable.</p> <p>*Willing to get vaccine defined as survey response of “very likely” or “somewhat likely”. Not willing to get vaccine defined as “not likely” or “not at all likely.” Women who responded “unknown” are not included in the analysis (n=103).</p> <p>†Among all employed (n=549)</p> <p>‡Defined as asthma, chronic lung, metabolic, hematologic, cardiovascular, renal, hepatic, neurologic, rheumatologic disease or hypertension.</p> <p>Total Missing/Decline to respond/Unknown: age (2, <1%), race/ethnicity (37, 4%), education (2, <1%), households below poverty level (15, 2%), marital status (11, 1%), employed (7, <1%), occupation (5, <1%), underlying conditions (1, <1%), previous COVID-19 (2, <1%), received influenza vaccine last year (21, 2%).</p> <p>Abbreviations: IQR, interquartile range.</p>				

433

434

Table 2. Logistic regression models evaluating factors associated with COVID-19 vaccine acceptance (n=803)		
	OR (95% CI)	aOR (95% CI) [†]
Site		
Birmingham, AL	1.4 (1.0-2.0)	
Salt Lake City, UT	3.6 (2.5-5.1)	
New York City, NY	Ref	
Age, years (n=802)		
18-34	0.8 (0.6-1.1)	
35-50	Ref	
Race/ethnicity (n=773)		
White, non-Hispanic	Ref	Ref
Black, non-Hispanic	0.3 (0.2-0.4)	0.4 (0.2-0.6)
Hispanic	0.3 (0.2-0.4)	0.4 (0.2-0.6)
Other, non-Hispanic	0.7 (0.3-1.4)	0.8 (0.4-1.7)
Education (n=802)		
Less than high school diploma	Ref	Ref
High school diploma	0.8 (0.4-1.5)	1.1 (0.5-2.1)
Some college or technical school	0.6 (0.3-1.2)	0.6 (0.3-1.2)
College degree	1.5 (0.8-2.8)	1.0 (0.5-2.0)
Graduate school degree	2.4 (1.3-4.7)	1.3 (0.6-2.8)
Household Below Poverty Level (n=791)		
Yes	0.9 (0.7-1.3)	
No	Ref	
Employed (n=797)		
Yes	1.2 (0.9-1.6)	
No	Ref	
Health Care Occupation (n=792)		
Yes	1.4 (1.0-1.9)	
No ^{††}	Ref	


Underlying Medical Condition[‡]		
≥1	1.0 (0.7-1.3)	
None	Ref	
Received Influenza Vaccine Last Year (n=784)		
Yes	2.6 (1.9-3.6)	2.1 (1.5-3.0)
No	Ref	Ref
<p>If data are missing for a variable, n included are indicated in parentheses after variable. Missing/Decline to Respond/Unknown answers not included in calculations.</p> <p>*Willing to get vaccine defined as survey response of “very likely” or “somewhat likely”. Not willing to get vaccine defined as “not likely” or “not at all likely.” Women who responded “unknown” are not included in the analysis (n=103).</p> <p>†Final adjusted model includes variables for which aOR reported above.</p> <p>††Includes women who are not employed.</p> <p>‡Defined as asthma, chronic lung, metabolic, hematologic, cardiovascular, renal, hepatic, neurologic, or rheumatologic disease or hypertension.</p> <p>Abbreviations: OR, odds ratio; CI, confidence interval; aOR, adjusted odds ratio</p>		

435

436

437 **FIGURES**


Figure 1. Pregnant women’s attitudes towards COVID-19 illness during pregnancy, N=915



438

439

Figure 2. Pregnant women’s attitudes towards SARS-CoV2 vaccination during pregnancy by race and ethnicity, N=906



440

441 Footnote: Women whose self-reported race/ethnicity was Other, non-

442 Hispanic (n=38) and women with unknown race/ethnicity (n=37) are not shown in

443 responses stratified by race and ethnicity.